FASN and triple-negative breast carcinoma: In a phase II trial(NCT02595372) to investigate the association between FASN inhibition and triple-negative breast cancer (TNBC), the research team treated 42 patients with oral omeprazole and observed the complete remission rate (pCR) of the surgical patients, the changes of FASN expression, enzyme activity, and downstream protein expression after omeprazole monotherapy, the safety and pharmacokinetics of omeprazole, etc., of which the pCR rate of all surgical patients was 74.4% (95% CI 57.9–87.0).